In an attempt to discover efficacious and safe treatments for COVID-19, the scientific community has been repurposing existing medications with proven track records. One of these established medication classes is statins – which have an excellent record as safe and affordable therapies. Ongoing research is examining the broader use of statins in COVID-19 patients with current evidence suggesting they may lower mortality rates and the incidence of severe complications.
The U.S. Centers for Disease Control and Prevention (CDC) and other health agencies are investigating a potential link between the COVID-19 vaccine and myocarditis. The condition has been reported at higher-than-usual rates in 12- to 39-year-old males within one week of receiving the second dose of the Pfizer or Moderna mRNA vaccine.
The U.S. Vaccine Adverse Event Reporting System (VAERS) vaccine safety monitoring system has reported an uptick in the number of patients experiencing heart inflammation, or myocarditis, after receiving mRNA COVID-19 vaccines. As of May 31, 2021, there were 475 reports of myocarditis among the recently vaccinated, primarily young men age 16 to 24, according VAERS data. Of the 475 cases, 226 met the CDC’s definition of a “working case” and will be investigated further through patient medical records.